While minimal-count MBL not often progresses to CLL, high-rely MBL progresses to CLL necessitating therapy in a charge of one% to two% each year. Superior-count MBL is distinguished from Rai 0 CLL determined by whether or not the B-cell count is previously mentioned or down below five × 109/L.